CO6260083A2 - Triazolopiridinas como inhibidores del par1 su produccion y su uso como medicamentos - Google Patents
Triazolopiridinas como inhibidores del par1 su produccion y su uso como medicamentosInfo
- Publication number
- CO6260083A2 CO6260083A2 CO10095026A CO10095026A CO6260083A2 CO 6260083 A2 CO6260083 A2 CO 6260083A2 CO 10095026 A CO10095026 A CO 10095026A CO 10095026 A CO10095026 A CO 10095026A CO 6260083 A2 CO6260083 A2 CO 6260083A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- cycloalkyl
- alkylene
- independently
- mono
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Un compuesto de la fórmula Iy/o cualquier forma estereoisomérica o tautomérica del compuesto de la fórmula I y/o mezclas de estas formas en cualquier proporción, y/o una sal fisiológicamente compatible del compuesto de la fórmula I, en la que Q1 es un átomo de hidrógeno, -alquilo (C1-C6), - cicloalquilo (C3-C6), -OH, -O-alquilo (C1-C6) o -O-cicloalquilo (C3-C6), donde cada uno de alquilo y cicloalquilo está sin sustituir o mono-, di- o trisustituido independientemente con -alquilo (C1-C4), -cicloalquilo (C3-C6), OH, -O-alquilo (C1-C6) o -O-cicloalquilo (C3-C6), donde algunos o todos los átomos de hidrógeno en el alquilo o cicloalquilo pueden reemplazarse por flúor, Q2 y Q3 son iguales o diferentes y cada uno es independientemente un átomo de hidrógeno, -alquilo (C1-C6) o -cicloalquilo (C3-C6), donde algunos o todos los átomos de hidrógeno en el alquilo o cicloalquilo pueden reemplazarse por flúor, R1, R2 y R3 son iguales o diferentes y cada uno es independientemente un átomo de hidrógeno, -alquilo (C1-C6), -cicloalquilo (C3-C6), -O-alquilo (C1-C8), -O-cicloalquilo (C3-C6), -alquileno (C0-C4)-C(O)-N(R11)-R12, -alquileno (C0-C4)-C(O)-O-R11, -alquileno (C0-C4)-C(O)- R11, -alquileno (C0-C4)-N(R11)-R12, -alquileno (C0-C4)-N(R11)-C(O)-R12, halógeno, OH, -CN, -NO2, -SO2CH3, -SO2CF3, -SF5, - Si[alquilo (C1-C4)]3, -alquileno (C1-C6)-O-alquilo (C1-C6), -O-alquileno (C1-C6)-O-alquilo (C1-C6), -O-alquileno (C0-C4)-arilo (C6-C14) donde el arilo está sin sustituir o mono-, di- o trisustituido independientemente con -O-alquilo (C1-C6), -alquilo (C1-C4), OH, -cicloalquilo (C3-C6) o O-cicloalquilo (C3-C6), -O-alquileno (C1-C4)-cicloalquilo (C3-C6) -Het (C4-C15) donde Het está sin sustituir o mono-, di- o trisustituido independientemente con -alquilo (C1-C4), -cicloalquilo (C3-C6), OH, -O-alquilo (C1-C6) o -O-cicloalquilo (C3-C6), o -O-alquileno (C1-C6)-O-alquileno (C1-C6)- O-alquilo (C1-C6), donde cada uno del alquilo, alquileno y cicloalquilo está sin sustituir o mono-, di-o trisustituido independientemente con-alquilo (C1-C4), - cicloalquilo (C3-C6), OH, -O-alquilo (C1-C6), -arilo (C6-C14), donde el arilo está sin sustituir o mono-, di-, tri-, tetra- o pentasustituido independientemente con halógeno, -alquilo (C1-C4), -cicloalquilo (C3-C6), ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290112 | 2008-02-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6260083A2 true CO6260083A2 (es) | 2011-03-22 |
Family
ID=39539711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10095026A CO6260083A2 (es) | 2008-02-05 | 2010-08-04 | Triazolopiridinas como inhibidores del par1 su produccion y su uso como medicamentos |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US8076336B2 (es) |
| EP (1) | EP2240487B1 (es) |
| JP (1) | JP5526040B2 (es) |
| KR (1) | KR20100114514A (es) |
| CN (1) | CN101981034B (es) |
| AR (1) | AR070410A1 (es) |
| AT (1) | ATE537172T1 (es) |
| AU (1) | AU2009211887B2 (es) |
| BR (1) | BRPI0907486A2 (es) |
| CA (1) | CA2713550C (es) |
| CL (1) | CL2009000236A1 (es) |
| CO (1) | CO6260083A2 (es) |
| CY (1) | CY1113228T1 (es) |
| DK (1) | DK2240487T3 (es) |
| ES (1) | ES2379447T3 (es) |
| HK (1) | HK1149011A1 (es) |
| HR (1) | HRP20120230T1 (es) |
| IL (1) | IL207205A0 (es) |
| MA (1) | MA32061B1 (es) |
| MX (1) | MX2010008490A (es) |
| MY (1) | MY152040A (es) |
| NZ (1) | NZ587141A (es) |
| PA (1) | PA8814801A1 (es) |
| PE (1) | PE20091455A1 (es) |
| PL (1) | PL2240487T3 (es) |
| PT (1) | PT2240487E (es) |
| RS (1) | RS52264B (es) |
| RU (1) | RU2499797C2 (es) |
| SI (1) | SI2240487T1 (es) |
| TW (1) | TW200946532A (es) |
| WO (1) | WO2009097970A1 (es) |
| ZA (1) | ZA201004467B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2066676A1 (en) * | 2006-09-18 | 2009-06-10 | Vertex Pharmaceuticals, Inc. | HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF |
| BRPI0907487A2 (pt) * | 2008-02-05 | 2015-07-14 | Sanofi Aventis | Sais de triazólio como inibidores de par1, produção dos mesmos e uso como medicamentos |
| US8673890B2 (en) | 2009-10-29 | 2014-03-18 | Janssen Pharmaceutica Nv | 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist |
| KR20220022895A (ko) * | 2019-06-19 | 2022-02-28 | 엔엠디 파마 에이/에스 | Clc-1 클로라이드 채널 억제제의 제조 방법 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4578464A (en) | 1983-11-22 | 1986-03-25 | Merrell Dow Pharmaceuticals Inc. | 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds |
| KR970706287A (ko) * | 1994-09-16 | 1997-11-03 | 다께다 구니오 | 트리아졸로피리다진의 제조 방법, 그의 제조를 위한 중간체 및 약제로서의 그의 용도(triazolopyridazines process and intermediates for their preparation and their use as medicaments) |
| US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| US7488742B2 (en) | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| BR0208985A (pt) * | 2001-04-19 | 2004-03-09 | Eisai Co Ltd | Derivados de 2-iminopirrolidina |
| EP1391452A4 (en) | 2001-05-25 | 2005-10-26 | Mochida Pharm Co Ltd | 4-HYDROXPIPERIDIN DERIVATIVE ANALGETIC EFFECT |
| US6984653B2 (en) | 2001-10-05 | 2006-01-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof |
| ATE525378T1 (de) | 2001-10-18 | 2011-10-15 | Schering Corp | Himbacinanaloga als thrombinrezeptorantagonisten |
| PL214718B1 (pl) | 2002-04-16 | 2013-09-30 | Schering Corp | Tricykliczny antagonista receptora trombinowego, zawierajaca go kompozycja farmaceutyczna i jego zastosowanie |
| CN100439336C (zh) | 2003-02-19 | 2008-12-03 | 卫材R&D管理有限公司 | 制备环状苯甲脒衍生物的方法 |
| TW200531688A (en) | 2004-03-05 | 2005-10-01 | Hoffmann La Roche | Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents |
| WO2006051648A1 (ja) | 2004-11-09 | 2006-05-18 | Eisai R & D Management Co., Ltd. | トロンビン受容体アンタゴニストを有効成分とするくも膜下出血に伴う血管攣縮の治療剤 |
| DK1966214T3 (en) * | 2005-12-21 | 2017-02-13 | Janssen Pharmaceutica Nv | TRIAZOLPYRIDAZINES AS TYROSINKINASA MODULATORS |
| DE102006025318A1 (de) * | 2006-05-31 | 2007-12-06 | Bayer Healthcare Ag | Dihydro-pyrrolopyridin-, Dihydro-pyrrolopyridazin- und Dihydro-pyrrolopyrimidin-Derivate und ihre Verwendung |
| DE102006036023A1 (de) * | 2006-08-02 | 2008-02-07 | Sanofi-Aventis | Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität |
| EP2242740B1 (de) | 2008-02-05 | 2012-12-12 | Sanofi | Sf5-derivate als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel |
| CA2713554C (en) | 2008-02-05 | 2016-09-06 | Sanofi-Aventis | Imidazopyridazines as par1 inhibitors, production thereof, and use as medicaments |
| BRPI0907487A2 (pt) | 2008-02-05 | 2015-07-14 | Sanofi Aventis | Sais de triazólio como inibidores de par1, produção dos mesmos e uso como medicamentos |
| US8394823B2 (en) | 2008-04-11 | 2013-03-12 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as DGAT1 inhibitors |
| WO2009126624A1 (en) | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolo compounds useful as dgat1 inhibitors |
-
2009
- 2009-01-23 JP JP2010545378A patent/JP5526040B2/ja not_active Expired - Fee Related
- 2009-01-23 CA CA2713550A patent/CA2713550C/en not_active Expired - Fee Related
- 2009-01-23 NZ NZ587141A patent/NZ587141A/en not_active IP Right Cessation
- 2009-01-23 EP EP09708289A patent/EP2240487B1/de active Active
- 2009-01-23 SI SI200930192T patent/SI2240487T1/sl unknown
- 2009-01-23 MY MYPI20103226 patent/MY152040A/en unknown
- 2009-01-23 PL PL09708289T patent/PL2240487T3/pl unknown
- 2009-01-23 RS RS20120103A patent/RS52264B/en unknown
- 2009-01-23 KR KR1020107017452A patent/KR20100114514A/ko not_active Application Discontinuation
- 2009-01-23 AU AU2009211887A patent/AU2009211887B2/en not_active Ceased
- 2009-01-23 ES ES09708289T patent/ES2379447T3/es active Active
- 2009-01-23 CN CN2009801115086A patent/CN101981034B/zh not_active Expired - Fee Related
- 2009-01-23 MX MX2010008490A patent/MX2010008490A/es active IP Right Grant
- 2009-01-23 BR BRPI0907486-4A patent/BRPI0907486A2/pt not_active IP Right Cessation
- 2009-01-23 RU RU2010136957/04A patent/RU2499797C2/ru not_active IP Right Cessation
- 2009-01-23 WO PCT/EP2009/000406 patent/WO2009097970A1/de active Application Filing
- 2009-01-23 AT AT09708289T patent/ATE537172T1/de active
- 2009-01-23 DK DK09708289.5T patent/DK2240487T3/da active
- 2009-01-23 PT PT09708289T patent/PT2240487E/pt unknown
- 2009-02-03 CL CL2009000236A patent/CL2009000236A1/es unknown
- 2009-02-03 AR ARP090100348A patent/AR070410A1/es not_active Application Discontinuation
- 2009-02-03 PE PE2009000154A patent/PE20091455A1/es not_active Application Discontinuation
- 2009-02-03 TW TW098103334A patent/TW200946532A/zh unknown
- 2009-02-03 PA PA20098814801A patent/PA8814801A1/es unknown
-
2010
- 2010-06-24 ZA ZA2010/04467A patent/ZA201004467B/en unknown
- 2010-07-25 IL IL207205A patent/IL207205A0/en unknown
- 2010-08-04 MA MA33059A patent/MA32061B1/fr unknown
- 2010-08-04 CO CO10095026A patent/CO6260083A2/es active IP Right Grant
- 2010-08-05 US US12/851,189 patent/US8076336B2/en not_active Expired - Fee Related
-
2011
- 2011-03-30 HK HK11103239.2A patent/HK1149011A1/xx not_active IP Right Cessation
- 2011-09-23 US US13/243,118 patent/US9079906B2/en not_active Expired - Fee Related
-
2012
- 2012-03-13 HR HR20120230T patent/HRP20120230T1/hr unknown
- 2012-03-14 CY CY20121100256T patent/CY1113228T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2018000089A (es) | Amidas heterocíclicas como inhibidores de cinasas | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| DK3699181T3 (da) | Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat | |
| PE20200387A1 (es) | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer | |
| HK1216527A1 (zh) | -二氫吡唑幷 吡嗪- -酮化合物及其作爲 受體的負性別構調節物的用途 | |
| SV2016005257A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| HK1220121A1 (zh) | 取代的 -二氫咪唑並 喹唑啉治療淋巴瘤的用途 | |
| PE20150666A1 (es) | Inhibidores de serina/treonina cinasa | |
| CR9398S (es) | Contenedor | |
| PE20141973A1 (es) | Compuestos de heterociclilo como inhibidores de mek | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| SG11201600821SA (en) | Waste incinerator ash as aerating agent for the manufacture of lightweight construction materials | |
| TR201900662T4 (tr) | Cb2 reseptör antagonistleri olarak triazolo[4,5-d]pirimidin türevleri. | |
| MY169118A (en) | Tracers | |
| UY30115A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en terapeutica | |
| GT200800075S (es) | Diseño de embudo | |
| AR093184A1 (es) | Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden | |
| GT200700098S (es) | Envase | |
| CR20150254A (es) | Compuestos quimicos | |
| WO2008111239A1 (ja) | 帯電防止剤およびその用途 | |
| CO6260083A2 (es) | Triazolopiridinas como inhibidores del par1 su produccion y su uso como medicamentos | |
| PE20170683A1 (es) | Triazolo[4,5-d]pirimidinas como agonistas del receptor canabinoide 2 | |
| CR20150555A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina | |
| CR20160198A (es) | Derivados de etinilo-imidazolidín-2, 4-diona como moduladore mglur4 | |
| PE20151669A1 (es) | Compuestos de azetidiniloxifenilpirrolidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |